Renal oncocytoma differential diagnosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 50: Line 50:
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology
|-  
|-  
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptom 1
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Central scar
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptom 2
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Papillary
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptom 3
 
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical exam 1
structures
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical exam 2
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Classic
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical exam 3
 
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab 1
architectural
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab 2
 
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab 3
pattern
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging 1
 
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Nuclei
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |CK7
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |KIT
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Vimentin
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |AMACR
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |SDHB
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Melanocytic
 
markers
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging 2
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging 2
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging 3
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging 3
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Oncocytoma
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Oncocytoma
| style="background: #F5F5F5; padding: 5px;" |Classic but
only subset
| style="background: #F5F5F5; padding: 5px;" |No or rare
abortive
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |+
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 83: Line 96:


RCC, eosinophilic
RCC, eosinophilic
| style="background: #F5F5F5; padding: 5px;" |Sometimes
| style="background: #F5F5F5; padding: 5px;" |No
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |+
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 102: Line 115:


RCC, classic
RCC, classic
| style="background: #F5F5F5; padding: 5px;" |Sometimes
| style="background: #F5F5F5; padding: 5px;" |No
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |+
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 121: Line 134:


RCC
RCC
| style="background: #F5F5F5; padding: 5px;" |Unknown
| style="background: #F5F5F5; padding: 5px;" |Usually no
(rare variant
cases)
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |- (mast
| style="background: #F5F5F5; padding: 5px;" |
 
| style="background: #F5F5F5; padding: 5px;" |
cells
 
present)
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 140: Line 161:


eosinophilic
eosinophilic
| style="background: #F5F5F5; padding: 5px;" |Usually not
| style="background: #F5F5F5; padding: 5px;" |Yes
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |-
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 159: Line 180:


RCC
RCC
| style="background: #F5F5F5; padding: 5px;" |Usually not
| style="background: #F5F5F5; padding: 5px;" |No
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |-
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 176: Line 197:
|-
|-
|Epithelioid AML
|Epithelioid AML
|Usually not
|No
|
|
|
|<nowiki>-</nowiki>
|
|
|
|
|
|

Revision as of 12:23, 2 May 2019

Renal oncocytoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Renal oncocytoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of choice

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Renal oncocytoma differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Renal oncocytoma differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Renal oncocytoma differential diagnosis

CDC on Renal oncocytoma differential diagnosis

Renal oncocytoma differential diagnosis in the news

Blogs on Renal oncocytoma differential diagnosis

Directions to Hospitals Treating Renal oncocytoma

Risk calculators and risk factors for Renal oncocytoma differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2] Shanshan Cen, M.D. [3]

Overview

Renal oncocytoma must be differentiated from renal cell carcinoma, metanephric neoplasms, and renal leiomyoma.

Differential Diagnosis

Renal oncocytoma must be differentiated from:

  • Metanephric adenoma
  • Metanephric adenofibroma

Overview

[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].

OR

[Disease name] must be differentiated from [[differential dx1], [differential dx2], and [differential dx3].

Differentiating [Disease name] from other Diseases

[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].

OR

[Disease name] must be differentiated from [differential dx1], [differential dx2], and [differential dx3].

OR

As [disease name] manifests in a variety of clinical forms, differentiation must be established in accordance with the particular subtype. [Subtype name 1] must be differentiated from other diseases that cause [clinical feature 1], such as [differential dx1] and [differential dx2]. In contrast, [subtype name 2] must be differentiated from other diseases that cause [clinical feature 2], such as [differential dx3] and [differential dx4].

Differentiating [disease name] from other diseases on the basis of [symptom 1], [symptom 2], and [symptom 3]

On the basis [symptom 1], [symptom 2], and [symptom 3], [disease name] must be differentiated from [disease 1], [disease 2], [disease 3], [disease 4], [disease 5], and [disease 6].

Diseases Clinical manifestations Para-clinical findings Gold standard Additional findings
Symptoms Physical examination
Lab Findings Imaging Histopathology
Central scar Papillary

structures

Classic

architectural

pattern

Nuclei CK7 KIT Vimentin AMACR SDHB Melanocytic

markers

Imaging 2 Imaging 3
Oncocytoma Classic but

only subset

No or rare

abortive

+
Chromophobe

RCC, eosinophilic

Sometimes No +
Chromophobe

RCC, classic

Sometimes No +
SDH-deficient

RCC

Unknown Usually no

(rare variant

cases)

- (mast

cells

present)

Papillary RCC,

eosinophilic

Usually not Yes -
Tubulocystic

RCC

Usually not No -
Epithelioid AML Usually not No -

References

  1. Renal oncocytoma.Dr Donna D'Souza et al. Radiopaedia.org 2015.http://radiopaedia.org/articles/renal-oncocytoma

Template:WH Template:WS